The pharmaceutical industry occupies a peculiar position in the global economy. It is simultaneously one of its largest and most strategically vital sectors, responsible for advancing public health, tackling complex diseases, and generating enormous financial returns, yet its companies are remarkably fragile organisms. Despite pouring billions into research and development and facing demand that only intensifies as populations age and chronic disease spreads, drug firms routinely vanish from the market, most often absorbed through mergers and acquisitions rather than collapsing into bankruptcy. Understanding why some pharmaceutical companies endure while others exit has now become the subject of one of the most comprehensive syntheses attempted in this field, a systematic review spanning nearly three decades of published research.
The study, conducted by a team of health economics researchers led by Nasim Jaberi and Vahid Alipour of Iran University of Medical Sciences together with Jalal Arabloo and Parviz Mohamadzadeh of the University of Tabriz, was published in BMC Health Services Research. The team set out to fill a conspicuous gap: while the broader literature on firm survival is vast, no comprehensive synthesis had focused specifically on pharmaceutical companies, an industry whose economics, regulatory burdens, and innovation cycles differ sharply from those of manufacturing or services. Their goal was to identify the key determinants of pharmaceutical company survival in a form useful to policymakers and decision-makers who shape the environment in which these firms operate.
Methodologically, the review was designed to the highest standards of evidence synthesis. The authors followed the PRISMA 2020 reporting guidelines and prospectively registered the protocol in PROSPERO under registration number CRD42024553565. They searched four major databases, PubMed, Scopus, Web of Science, and ProQuest, without applying any date restriction, and supplemented these searches with additional sources. Crucially, they restricted inclusion to quantitative studies that employed formal survival analysis methods to examine the survival or exit of pharmaceutical companies, whether through mergers, acquisitions, bankruptcy, or other forms of market departure. Data extraction used a standardized form capturing study characteristics, analytical methods, variables, and findings, and because the included studies were statistically and conceptually heterogeneous, the team performed a narrative synthesis rather than a pooled meta-analysis.
The scale of the screening exercise was formidable. The initial search returned 35,129 records, which the authors distilled down to 58 included studies published between 1995 and 2024. More than half of these studies, 58.62 percent, appeared in the last decade, a signal that questions of pharmaceutical firm longevity have grown sharply in academic urgency as the industry consolidates. Geographically, the evidence base was heavily skewed: the vast majority of studies came from high-income countries, with the United States dominating the landscape. This concentration matters, because the determinants of survival in a mature, heavily regulated, capital-rich market may differ substantially from those in emerging pharmaceutical economies, a limitation the authors acknowledge explicitly.
On the technical side, two statistical workhorses dominated the field. The Cox proportional hazards model, which estimates how covariates multiply the instantaneous hazard of exit at any point in time, was the most common analytical method, followed closely by logistic regression, which models the probability of exit over a defined period. The prevalence of Cox models reflects the field’s reliance on time-to-event data, where firms are tracked from entry or a baseline year until they exit, are acquired, or the observation window closes. These methods allow researchers to handle censored observations, firms still alive when the study ends, which is essential in survival research, though the authors note that methodological choices varied considerably across the 58 studies, contributing to the heterogeneity that precluded quantitative pooling.
The heart of the review is its taxonomy of survival determinants. From the 58 studies, the team extracted 63 distinct factors influencing pharmaceutical company survival, which they organized into five categories: firm-specific characteristics, industry-specific conditions, macroeconomic conditions, geographic conditions, and owner or manager characteristics. The firm-specific group proved the richest, encompassing attributes such as company size, age, financial performance, and innovation-related activity. Industry-specific factors centered on market competition, while macroeconomic and geographic categories captured the broader economic and regional environments in which firms operate. The fifth category, owner and manager characteristics, acknowledged that the identities, experience, and decisions of those who run pharmaceutical firms shape their fate in ways that balance sheets alone cannot capture.
Among these 63 factors, five emerged as the most frequently studied: firm size, firm age, market competition, innovation-related activities, and financial performance. Yet the most striking finding is how unsettled the evidence remains. For each of these headline determinants, the review found mixed results regarding their impact on survival. Larger firms, for instance, may benefit from economies of scale, diversified portfolios, and deeper pockets for regulatory compliance, but they can also become acquisition targets or suffer bureaucratic inertia. Younger firms face the liability of newness, yet in an industry where a single blockbuster drug can transform a startup, age is no simple shield. Intense competition can weed out weak players or, alternatively, spur the innovation that keeps strong ones alive. The authors conclude that the impact of many determinants is ambiguous and heavily context-dependent, a sobering verdict for anyone hoping for a simple formula for longevity.
This ambiguity does not render the synthesis useless; rather, it reframes the policy question. Because survival determinants interact with context, the authors argue, policymakers should pursue targeted interventions tailored to firm circumstances rather than blanket measures. Their recommendations, grounded in the patterns across the 58 studies, include financial and regulatory support specifically designed for small pharmaceutical firms, which face disproportionate survival risks; incentives for high-risk research and development, where the social value of innovation exceeds what private actors can justify; streamlined drug approval pathways that reduce the fixed costs of regulation; mentorship programs connecting experienced industry leaders with emerging companies; and workforce development initiatives to secure the specialized human capital the industry requires. Each proposal maps onto one or more of the determinant categories the review identified, translating an academic taxonomy into an actionable agenda.
The review also maps the frontier of ignorance. Firm-specific and industry-specific factors have absorbed most of the scholarly attention, while macroeconomic, geographic, and ownership-related determinants remain comparatively underexplored. The geographic skew of the evidence base compounds the problem: with studies concentrated in the United States and other high-income settings, the survival dynamics of pharmaceutical firms in middle- and low-income countries, where generic manufacturers and emerging biotech sectors are often most vulnerable, are largely invisible in the quantitative record. The authors call explicitly for future research to focus on these understudied regions and on contextual factors, arguing that only a more globally representative evidence base can support the kind of differentiated policy the industry’s heterogeneity demands.
For an industry that underwrites modern medicine, the fragility documented here carries consequences far beyond shareholders. Every merger that folds a research pipeline into a larger acquirer, every bankruptcy that orphans a promising compound, represents a potential loss for patients and public health systems. By systematically cataloguing what three decades of survival analysis have revealed, and just as importantly what they have not, this review provides the first comprehensive map of the terrain on which pharmaceutical companies live and die. Its message is double-edged: the levers of survival are known in outline, size, age, competition, innovation, and finances chief among them, but pulling them effectively requires understanding the context in which each firm operates. In a sector where the stakes are measured in lives as much as in revenue, that nuance is not an academic nicety. It is the difference between policy that strengthens the industry’s resilience and policy that merely reshuffles its wreckage.
Subject of Research: Determinants of survival and exit among pharmaceutical companies
Article Title: Critical survival factors in the pharmaceutical industry: a systematic review of methodologies and determinants from 1995 to 2024
Article References: Critical survival factors in the pharmaceutical industry: a systematic review of methodologies and determinants from 1995 to 2024. (n.d.). https://doi.org/10.1186/s12913-026-15639-z
Image Credits: AI Generated
DOI: 10.1186/s12913-026-15639-z
Keywords: pharmaceutical industry, firm survival, systematic review, survival analysis, Cox proportional hazards model, mergers and acquisitions, innovation, market competition, health economics, R&D investment, pharmaceutical policy, firm size
News Source: Ophelia Keating. (October 13, 2026). What Keeps Drug Companies Alive? Three Decades of Evidence Distilled. Scienmag.
